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Abstract
Limb girdle muscular dystrophy type 2L or anoctaminopathy is a condition
mainly characterized by adult onset proximal lower limb muscular weakness
and raised CK values, due to recessive ANO5 gene mutations. An exon 5
founder mutation (c.191dupA) has been identified in most of the British and
German LGMD2L patients so far reported. We aimed to further investigate
the prevalence and spectrum of ANO5 gene mutations and related clinical
phenotypes, by screening 205 undiagnosed patients referred to our molecular
service with a clinical suspicion of anoctaminopathy. A total of 42 unrelated
patients had two ANO5 mutations (21%), whereas 14 carried a single change. We
identified 34 pathogenic changes, 15 of which are novel. The c.191dupA mutation
represents 61% of mutated alleles and appears to be less prevalent in non-
Northern European populations. Retrospective clinical analysis corroborates the
prevalently proximal lower limb phenotype, the male predominance and absence
of major cardiac o...
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ABSTRACT: Limb girdle muscular dystrophy type 2L or
anoctaminopathy is a condition mainly characterized by
adult onset proximal lower limb muscular weakness and
raised CK values, due to recessive ANO5 gene mutations.
An exon 5 founder mutation (c.191dupA) has been iden-
tified in most of the British and German LGMD2L pa-
tients so far reported. We aimed to further investigate
the prevalence and spectrum of ANO5 gene mutations
and related clinical phenotypes, by screening 205 undi-
agnosed patients referred to our molecular service with a
clinical suspicion of anoctaminopathy. A total of 42 unre-
lated patients had two ANO5 mutations (21%), whereas
14 carried a single change. We identified 34 pathogenic
changes, 15 of which are novel. The c.191dupA mutation
represents 61% of mutated alleles and appears to be less
prevalent in non-Northern European populations. Ret-
rospective clinical analysis corroborates the prevalently
proximal lower limb phenotype, the male predominance
and absence of major cardiac or respiratory involvement.
Identification of cases with isolated hyperCKaemia and
very late symptomatic male and female subjects confirms
the extension of the phenotypic spectrum of the disease.
Anoctaminopathy appears to be one of the most common
adult muscular dystrophies in Northern Europe, with a
prevalence of about 20%–25% in unselected undiagnosed
cases.
HumMutat 34:1111–1118, 2013. C© 2013Wiley Periodicals, Inc.
KEYWORDS:ANO5; LGMD2L; gender; muscular dystro-
phy
Introduction
Limbgirdlemuscular dystrophy type2L (LGMD2L) is a condition
characterized by proximal weakness affecting primarily the pelvic
girdle and leg muscles, with less prominent distal leg weakness and
high CK values [Hicks et al., 2011]. LGMD2L, together with a more
distal variant also known as nondysferlin Miyoshi muscular dystro-
phy type 3 (MMD3) as well as some cases of isolated hyperCKaemia
and pseudometabolic myopathy, have been shown to be associated
with recessive mutations in the ANO5 gene [MIM #608662; Bolduc
et al., 2010; Bouquet et al., 2012; Deschauer et al., 2011; Hicks
et al., 2011; Magri et al., 2012; Milone et al., 2012; Little et al., 2013;
Neusch et al., 2012; Penttila¨ et al., 2012; Pe´nisson-Besnier et al.,
2012; Schessl et al., 2012; Wahbi et al., 2012; Witting et al., 2012].
The prevalence of ANO5 gene related conditions, or so-called anoc-
taminopathies, is not yet fully established, but preliminary data from
Northern England indicate that LGMD2L is the 3rd most common
type of LGMDwith aminimumprevalence of 0.27/100 000 [Hicks et
al., 2011]. To date, 67 variants (35 pathogenic; www.lovd.nl/ANO5)
have been detected all over the ANO5 gene, with one a common
mutation (c.191dupA) in exon 5, likely the result of a founder ef-
fect of Northern European origin [Hicks et al., 2011], and another
in exon 20 (c.2272C>T) more frequent in the Finnish population
[Penttila¨ et al., 2012]. Early clinical and MRI studies indicated wide
clinical heterogeneity and a gender difference in expression, with
anoctaminopathies appearing to be less frequent and less severe in
females [Sarkozy et al., 2012].
In the present study, we investigated the prevalence and spectrum
of ANO5 gene mutations in the so far largest and clinically most
heterogeneous cohort of patients with anoctaminopathy, to better
describe thephenotype, genderpredominance, and allelic variability
of this emerging disease.
Materials and Methods
The study was performed on a total of 205 unrelated individu-
als of both sexes, referred for ANO5 gene analysis to the Newcastle
upon Tyne Limb-Girdle Referral Centre in view of their phenotypes
compatible with anoctaminopathy, ranging from isolated hyperCK-
aemia, myalgia and raised CK, to MMD3 and LGMD2L. Patients
were referred from different clinical centers, but primarily from
the UK, Germany, France, Spain, the USA and Belgium. The co-
hort previously reported by Hicks et al. (2011) was not included in
this study. Clinical details for patients with ANO5 mutations were
collected retrospectively. The clinical suspicion of anoctaminopa-
thy was made following clinical examination, muscle assessment
and clinical investigations including CK analysis, EMG, muscle
MRI and/or muscle biopsy. Possible alternative diagnoses, such as
LGMD2B, LGMD2I, and LGMD2A, were excluded as appropriate.
DNAs of affected and unaffected relatives were collected and segre-
gation analysis performed where available.
DNA extraction and direct sequencing of the ANO5 gene (Gen-
Bank accession number NM 213599.2) was performed as described
elsewhere [Hicks et al., 2011]. Sequence variants were coded re-
flecting cDNA numbering with +1 corresponding to the A of the
ATG translation initiation codon in the reference sequence, accord-
ing to guidelines (www.hgvs.org/mutnomen). The initiation codon
is codon 1. Novelty of each sequence variant was checked in the
ANO5 locus specific database (www.lovd.nl/ANO5). To investigate
whether novel missense, synonymous or intronic variations not lo-
cated in splice sites could possibly represent pathogenic sequence
variants, we performed in silico analysis using the Alamut mutation
analysis software (Interactive Biosoftware, v2.1).
Results
Genetic Analysis
ANO5 gene sequence variants were identified in 90/205 unrelated
individuals (44%) and five affected relatives (Table 1, Supp. Table
S1). Fifty-one patients were found to carry two or more ANO5 vari-
ants in homozygosity or compound heterozygosity, whereas further
39 patients showed one singleANO5 change (Tables 1 and 2). A total
of 42 ANO5 gene variants were identified, 27 of which novel (Ta-
bles 1 and 2). Twenty variants were missense (47%), four frameshift
(9%), five splice site (12%), two stop (5%), one synonymous (2%),
and 10 intronic (24%) (Table 2). The pathogenicity of 15 novel
variants is supported by their predicted effect on protein product,
by their recurrence in multiple unrelated patients, by segregation in
affected family members, absence in SNPs databases and in silico
analysis. Four missense changes, two of which were previously re-
ported in literature as pathogenic (c.155A>G and c.2387C>T), were
considered benign variants based on in silico analysis and/or their
frequency in control population (Table 2) [Wahbi et al., 2012]. It was
not possible to further comment on the pathogenicity of a missense
(c.968C>G) and a synonymous change (c.2256G>A) as well as 10
intronic variants in absence of segregation studies or further cDNA
investigations.
Forty-two unrelated patients (N.1-N.42) carried two likely
pathogenic ANO5 gene changes, 19 in homozygosity and 23 in
compound heterozygosity (Table 1). Patients N.21B, N.22B, N.28B,
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Table 1. Patients with ANO5 Gene Mutations
Patient Allele 1 Allele 2 Geographic origin
Patients with two pathogenic variants
N.01-N.16 c.191dupA c.191dupAa Great Britain (12);
Germany 3);
Norway (1)
N.17-N22B c.191dupA c.692G>T Great Britain (7)
N.23 c.191dupA c.762+1G>A Great Britain
N.24 c.191dupA c.1391C>A USA
N.25 c.191dupA c.1407+5G>T Belgium
N.26-N.27 c.191dupA c.1627dupA Spain, n.a.
N.28A-N.28B c.191dupA c.1643C>T Germany (2)
N.29 c.191dupA c.1733T>C Great Britain
N.30-N.32 c.191dupA c.1898+1G>A Great Britain,
Poland and USA
N.33 c.191dupA c.2395C>T Great Britain
N.34 c.191dupA c.2417A>G USA
N.35 c.191dupA c.2272C>T Germany
N.36 c.401A>G c.1898+1G>A Great Britain
N.37 c.1639C>T c.1639C>T n.a.
N.38 c.2030–1G>T c.2030–1G>T Sri Lanka
N.39 c.2236–13 2236–
4delins
ATTCTTCTGGC
c.2236–13 2236–
4delins
ATTCTTCTGGC
Great Britain
N.40A-N.40C c.242A>G c.1097A>G Germany (3)
N.41 c.400C>T c.2235+1G>A France
N.42 c.989dupT c.2018A>G Great Britain
Patients with one pathogenic variant
N.43-N.44 c.191dupA c.155A>G Great Britain; n.a.
N.45-N.47 c.191dupA – Germany (2);
Great Britain
N.48-N.50 c.692G>T – Great Britain (3)
N.51 c.762+1G>A c.155A>G USA
N.52 c.1925G>T c.1181–21T>A Great Britain
N.53 c.1640G>A – Great Britain
N.54 c.2417A>G – Great Britain
N.55 c.2521C>G – Great Britain
N.56 c.2593A>C – Pakistan
aPatient N.05 and N.13 also with variant c.364–67T>C with uncertain pathogenicity.
ANO5 gene, GenBank accession number NM_213599.2. Nucleotide numbering re-
flects cDNA numbering with +1 corresponding to the A of the ATG transla-
tion initiation codon in the reference sequence, according to journal guidelines
(www.hgvs.org/mutnomen). The initiation codon is codon 1.
N.40B-C carried the pathogenic variants found in their affected rel-
ative (i.e., N.21A, N.22A, N.28A and N.40A). In 14 patients (N.43-
N.56) only one single pathogenic variant was identified. cDNA anal-
ysis or genomic dosage analysis was not performed to rule out a
possible 2nd deep intronic change or deletion/duplication of the
part/entire ANO5 gene. Seven novel pathogenic variants were re-
current (Tables 1 and 2). The common c.191dupA exon 5 mutation
was found in homozygosity in 16 patients, in compound heterozy-
gosity with another identifiedmutation in 19, and in heterozygosity
without a second detectable mutation in further five individuals.
Geographic origin of patients, indicated in Table 1, confirms that
the common variant is present also in populations other than the
British andGerman populations. Additionally, two already reported
(c.692G>T, c.1927dupA) and two novel (c.1898+1G>A, c.2417A>G)
mutations were also identified in multiple patients, and further
three novel changeswere found inhomozygosity in three individuals
(Tables 1 and 2). Parental DNA screening or ANO5 genomic dosage
analysis was not performed yet for the homozygous patients, and
hemizygosity of parts or the entireANO5 locus cannot be ruled out.
Phenotypic Analysis
Among patients with two likely pathogenic changes (total 47 pa-
tients, including 42 unrelated subjects and five affected relatives),
39 were male (83%) and eight were female (17%). Clinical infor-
mation was available for 44 patients (34 males, and seven females)
(Table 3). Age at onset ranged between teens and late 70s, with
an average age at onset of 35 years. At time of genetic diagnosis,
3/7 females and 3/4 males were completely asymptomatic or very
mildly symptomatic. Average CK values were 4,000 IU/l, ranging
from around 200 IU/l up to about 30,000 IU/l. Detailed information
about last muscle assessment was available for 38/47 individuals. A
predominantly proximal involvement was observed in 22/38 (57%)
patients, whereas 4/38 (10%) and 3/38 (8%) patients showed amore
distal or proximal plus distal involvement, respectively. No or very
mild clinical symptoms (myalgia and/or raised CK) were reported
in nine patients with two ANO5mutations (25%).
Symptoms at onset and overall clinical presentation in males
were similar to what has been previously described for patients with
ANO5 gene mutations (Table 3; Hicks et al., 2011]. Although age at
onset was similar on average (34 years), in this cohort we observed a
wider range, with patients showing first symptoms in their teens to
patients only symptomatic in late adulthood, with one patient (Pt.
N.38) showing first symptoms of proximal lower limbweakness and
wasting at the age of 77 years only. Moreover, the phenotype was
extremely mild in three individuals, only showing raised CK values
(Pt. N.15 and N.36) or some mild proximal leg weakness after a
disease course of 32 years (Pt. N40B). Patient N.21B was diagnosed
as part of family screening and showed no symptoms of the disease.
CK values were not available at the time of study.
Five female individuals (N.03, N.21A, N.27, N.28B, 40C), with
an age at last assessment ranging from 14 to 68 years, showed raised
CK values only or asymmetric calf atrophy, whereas female patients
N.02 and N.14, aged 68 and 42 years, respectively, showed a more
pronounced LGMD type weakness. Female patient N.08 (not in-
cluded in Table 3 in view of lack of detailed clinical information)
was diagnosed as part of a family screening of a previously reported
LGMD2L patient. At the age of 44 years she does not report any
clinical symptoms, but no further clinical information was available
at time of the study.
A total of seven unrelated patients were confirmed with anoc-
taminopathy, but did not carry the common c.191dupA mutation
on either allele. Age at onset was 44 years on average. Four patients
showed amilder phenotype,with a very late onset (77 years), normal
power or only mild proximal weakness at last assessment. Muscle
wasting was present in half of them, whereas upper limb function
was normal in all.
Clinical information was available for 11/14 unrelated patients
with one single pathogenic variant (data not shown). Five individ-
uals showed a phenotype compatible with a diagnosis of LGMD2L,
whereas three subjects only showed raised CK values with or with-
out calf hypertrophy. In one individual (Pt N.50) this variant was
also found in further two family members also affected by isolated
hyperCKaemia.
Discussion
In this study, we report on the clinical analysis and molecu-
lar screening of the ANO5 gene in the largest cohort of anoc-
taminopathy patients identified so far. Our results confirm the high
frequency of the common c.191dupA mutation which represents
51/84 (61%) of mutated alleles in the cohort of patients with two
mutations (Tables 1 and 2). Occurrence of this Northern European
founder mutation in patients of different geographic origin indi-
cates that it has likely spread worldwide, although at lower frequen-
cies compared with the British and German populations. This is
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Table 2. List of Detected ANO5 Gene Changes
Amino acidic Exon Protein
Nucleotidic change change intron domain Zygosity Reported Interpretation?
c.139–59dupT IVS3 CTD 1 HzPt Novel Benign in silico
c.155A>G p.Asn52Ser 4 CTD 3 CHzPt + 2 HzPt Reported Benign in silico
c.191dupA 5 CTD 16 HomoZpt+ 19 CHzPt + 5 HzPt Reported Frameshift mutation
c.242A>G p.Asp81Gly 5 CTD 1 CHzPt Reported Pathogenic missense change
c.364–8delT IVS7 CTD 5 HomoZpt+ 8 HzPt Reported Unconfirmed pathogenicity
c.364–67T>C IVS7 CTD 2 HzPt Novel Unconfirmed pathogenicity
c.400C>T p.His134Tyr 7 CTD 1 CHzPt Novel Pathogenic in silico
c.401A>G p.His134Arg 7 CTD 1 CHzPt Novel Pathogenic in silico
c.692G>T p.Gly231Val 8 CTD 5 CHzPt+ 3 HzPt Reported Pathogenic missense change
c.746C>G Ala249Gly 8 CTD 1 HzPt Novel Benign in silico
c.762+1G>A IVS8 CTD 1 CHzPt+1 HzPt Novel Putative splice mutation
c.878+78delT IVS9 CTD 1 HzPt Novel Benign in silico
c.879–41A>T IVS9 CTD 1 HzPt Novel Unconfirmed pathogenicity
c.968C>G p.Ala323Gly 10 CTD 1 HzPt Novel Unconfirmed pathogenicity
c.989dupT 10 CTD 1 CHzPt Novel Frameshift mutation
c.1097A>G p.Asn366Ser 11 ETD 1 1CHzPt Reported Pathogenic in silico
c.1119+35G>A IVS11 ETD 1 1 CHzPt Novel Unconfirmed pathogenicity
c.1120–24A>T IVS12 ETD1 2 HzPt Novel Unconfirmed pathogenicity
c.1181–21T>A IVS13 TMD2 1 HzPt Novel Unconfirmed pathogenicity
c.1181–48T>A IVS13 TMD2 1 CHzPt +8 HzPt Novel Unconfirmed pathogenicity
c.1391C>A Ala464Asp 14 TMD3 1 CHzPt Novel Pathogenic in silico
c.1407+5G>T IVS14 TMD3 1 CHzPt Reported Putative splice mutation
c.1627dupA 15 CTD3 2 CHzPt Reported Frameshift mutation
c.1639C>T p.Arg547STOP 16 CTD3 1 HomoZpt Novel Stop mutation
c.1640G>A p.Arg547Gln 16 CTD3 1 HzPt Novel Pathogenic in silico
c.1643C>T pThr548Ile 16 CTD3 1 CHzPt Reported Pathogenic in silico
c.1733T>C Phe578Ser 16 CTD3 1 CHzPt Reported Pathogenic missense change
c.1898+1G>A IVS17 ETD3 4 CHzPt Reported Putative splice mutation
c.1925G>T Arg642Leu 18 ETD3 1 HzPt Novel Pathogenic in silico
c.2018A>G Tyr673Cys 18 ETD3 1 CHzPt Reported Pathogenic missense change
c.2030–1G>T IVS18 1 HomoZpt Novel Putative splice mutation
c.2235+1G>A IVS19 TMD7 1 CHzPt Novel Putative splice mutation
c.2236–13 2236– 20 TMD7 1 HomoZpt Novel Frameshift mutation
4delinsATTCTTCTGGC
c.2256G>A 20 TMD7 1 HzPt Novel Unconfirmed pathogenicity
c.2272C>T Arg758Cys 20 TMD7 1 CHzPt Reported Pathogenic missense change
c.2387C>T p.Ser796Leu 20 TMD7 1 HzPt Reported Benign in silico
c.2395C>T p.Arg799STOP 20 1 CHzPt Novel Stop mutation
c.2417A>G p.Tyr806Cys 21 ETD4 1 CHzPt+ 1 HzPt Novel Pathogenic in silico
c.2521–13A>G IVS21 TMD8 1 HzPt Reported Unconfirmed pathogenicity
c.2521C>G p.His841Asp 22 TMD8 1 HzPt Novel Pathogenic in silico
c.2593G>T p.Ile865Leu 22 TMD8 1 HzPt Novel Pathogenic in silico
c.2698A>C p.Met900Leu 22 CTD5 1 HzPt Novel Benign in silico
ANO5 gene, GenBank accession number NM_213599.2. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon
in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.
CTD: cytoplasmic topological domain; ETD: extracellular topological domain; TMD: transmembrane domain; CHzPt: compound heterozygous patient, HzPt: heterozygous
patient; HomoZpt: homozygous patient; IVS: intron.
corroborated by the observation that the mutation has not been
observed in homozygosity in other populations, with the exception
of two unrelated French patients [Wahbi et al., 2012]. However, our
result could have been biased by the predominance of British and
German patients in our cohort.
We identified 27 novel variants in the ANO5 gene, 15 of which
are likely pathogenic (Tables 1 and 2). Mutations are spread across
the gene, indicating the absence of additional mutation hot spots,
although some mutations appear to be recurrent (Tables 1 and
2). The frequency of the second most common variant (c.692G>T)
suggests that it could represent an additional common change in our
population (Table 1). Interestingly, the common Finnish mutation
appears to be rare in our cohort, with a single occurrence in a
German patient in compound heterozygosity with the c.191dupA
mutation (Pt N.35). Mutations leading to loss of protein function
(frameshift, splice and stop mutations) were the most common
changes in the “2-mutation” group of patients (66/84 alleles, 79%)
although the relative frequency of missense changes (18/84 alleles,
21%) could imply further pathogenetic mechanisms.
We have identified several exonic changes that appear to be be-
nign variants or to have uncertain pathogenicity. Among these, the
nonpathogenic variant c.155A>G (p.Asn52Ser) in exon 4 (dbSNP
rs143777403), foundwith allelic frequency of 0.0001–0.001 inNorth
American and African American control populations, was identi-
fied in five patients from our cohort. The c.2387C>T (p.Ser796Leu)
in exon 22, also a benign variant by in silico analysis, was found
in another individual. Interestingly, these two missense variants
were described as pathogenic by Wahbi and coauthors (2012) in
three unrelated subjects, one of which was compound heterozy-
gous for this and the c.155A>G variant. These findings point toward
caution when novel missense changes are found (especially if in
compound heterozygosity), and no further data corroborating the
pathogenicity of the change is available. We identified three patients
who were homozygous for a novel variant and 14 patients with one
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heterozygous change only. One of the limitations of this study is the
lack of cDNA studies to exclude second deep intronic changes or
gene dosage analysis, but deletion/duplication analysis is currently
in progress in some of these individuals.
We have previously described the clinical phenotype of anoc-
taminopathies as an adult onset disease, characterized by slowly
progressive muscle weakness mainly affecting the pelvic girdle and
the lower limbs [Hicks et al., 2011]. Clinical analysis of the present
cohort of patients extends our initial findings to a large group of
patients not restricted to the common founder mutation (Table 3).
Being our center the only currently offering ANO5 screening in the
UK, the prevalence of proximal disease is unlikely to be caused by
the referral bias previously suggested [Hicks et al., 2011]. No major
significant cardiac or respiratory diseasewas observed in this cohort,
suggesting that these arenotmajor features of the condition.Wepro-
vide further evidence formale predominance in anoctaminopathies,
females being overall less frequently and less severely affected than
males [Hicks et al., 2011, Penttila¨ et al., 2012]. Phenotypic analysis
of the here reported affected females reveals amilder clinical picture,
with five patients showing only raisedCK values or calf hypertrophy.
The oldest female individual, homozygous for the common exon 5
mutation, showed a late disease onset (64 years), and at the age of
68 years she was still ambulant and she was able to stand on tiptoes
and heels withminor difficulties. These findings suggest that gender
differences could be in part due to the milder phenotype of affected
females that is therefore less likely to be ascertained. In fact, two
asymptomatic females were identified after a molecular diagnosis
was reached in their brothers. Recruitment bias could also in part
be responsible for gender difference, as patients seen in specialized
centers usually showamore severe phenotype, and therefore females
with milder phenotypes might not come as frequently to our atten-
tion. In this study, we also identified four male subjects showing a
very mild phenotype, ranging from isolated hyperCKaemia to mild
proximal leg weakness with onset in late adulthood (Table 3). In
particular, one subject only showed symptoms in his late 70s, con-
firming that indeed age at onset and severity of anoctaminopathies
can be extremely variable also in males (Hicks et al., 2011; Penttila¨
et al., 2012; Schessl et al., 2012].
No genotype–phenotype correlations were noted in anoc-
taminopathy so far. Nevertheless, a clinical comparison between
patients carrying the common exon 5 mutation and those carrying
different changes revealed some interesting findings (Tables 1 and
3). Pattern of muscle involvement and female/male ratio appear
similar, although the phenotype is somehow milder, with onset at
later age in patients carrying mutations other than the c.191dupA.
Unfortunately the relatively low number of patients with different
ANO5 changes does not allow any statistically significant conclu-
sions. Conversely, phenotypic analysis of heterozygous patients did
not evidence major differences compared with patients with two
mutations, although three heterozygous patients presented raised
CK values and mild calf hypertrophy only. Although we cannot ex-
clude a second non-yet identified change in these subjects, family
analysis of one individual (Pt. N.50) showed that raised CK val-
ues segregated with the heterozygous mutation in two other family
members (data not shown). An association between isolated hyper-
CKaemia and ANO5 heterozygous carrier status was suggested by
Milone and coworkers, who identified an otherwise asymptomatic
carrier of the c.191dupA mutation (Milone et al., 2012). Likewise,
isolated hyperCKaemia or very mild phenotypes were also found
in a few male and female patients carrying two pathogenic ANO5
mutations [Hicks et al., 2011; Penttila¨ et al., 2012; Schessl et al.,
2012; Wahbi et al., 2012]. Systematic analysis of ANO5 gene in
wider cohort of subjects with isolated hyperCKaemia, as well as CK
measurements in otherwise healthy heterozygous family members
could help to clarify these findings.
Our results show that ANO5 gene mutations are responsible for
about 1/4 of cases of undiagnosed muscular dystrophy with adult
onset and raised CK, screened at our service over the last two years
(present series and Hicks et al., 2011]. This value is similar to what
reported in the Finnish population [Penttila¨ et al., 2012] and indi-
cates anoctaminopathy as one of the most common form of LGMD
inour population, possible reflection of the founder effects observed
inNorthernEurope [Hicks et al., 2011]. Indeed, observed incidences
in the UK and Finland are higher than in Italy [Magri et al., 2012]
where only about 2% of undiagnosed LGMD patients were shown
to carry ANO5mutations. Based on its relative frequency, screening
of the ANO5 gene now represents an early step in the diagnostic
work-up of these patients. However, in view of the increasing ge-
netic heterogeneity and prevalence of families without the common
mutation (14%), analysis should not be limited to founder muta-
tions only [Penttila¨ et al., 2012]. More systematic studies on isolated
hyperCKaemia patients will also help in giving better prevalence
data for anoctaminopathies in general.
In conclusion, we confirmed that ANO5 gene mutations are re-
sponsible for about 1/4 of cases of undiagnosed muscular dystrophy
in our population, being the exon 5 change the most prevalent. We
expanded the allelic heterogeneity of the disease and recognized a
broader clinical spectrum of the disease, ranging from isolated hy-
perCKaemia to full blown LGMD2L, with clear male predominance
both in terms of overall prevalence and severity of the disease.
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